Invesco
CSTL icon

Invesco’s Castle Biosciences CSTL Stock Holding History

Invesco’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
54,888
-6,124
-10% -$136K ﹤0.01% 2786
2026
Q1 		$1.5M Sell
61,012
-74,449
-55% -$2.44M ﹤0.01% 2685
2025
Q4 		$5.27M Buy
135,461
+79,621
+143% +$2.57M ﹤0.01% 2227
2025
Q3 		$1.27M Buy
55,840
+15,411
+38% +$313K ﹤0.01% 2824
2025
Q2 		$826K Buy
40,429
+8,178
+25% +$151K ﹤0.01% 2926
2025
Q1 		$646K Buy
32,251
+4,717
+17% +$117K ﹤0.01% 3049
2024
Q4 		$734K Buy
27,534
+616
+2% +$18.8K ﹤0.01% 3048
2024
Q3 		$768K Sell
26,918
-130
-0.5% -$3.31K ﹤0.01% 3030
2024
Q2 		$589K Sell
27,048
-348
-1% -$7.75K ﹤0.01% 3208
2024
Q1 		$607K Sell
27,396
-4,760
-15% -$104K ﹤0.01% 3235
2023
Q4 		$694K Sell
32,156
-3,801
-11% -$66.9K ﹤0.01% 3058
2023
Q3 		$607K Buy
35,957
+12,238
+52% +$214K ﹤0.01% 3110
2023
Q2 		$325K Buy
23,719
+814
+4% +$16.5K ﹤0.01% 3463
2023
Q1 		$520K Buy
22,905
+3,782
+20% +$92.4K ﹤0.01% 3242
2022
Q4 		$450K Sell
19,123
-326,856
-94% -$7.58M ﹤0.01% 3325
2022
Q3 		$9.02M Sell
345,979
-2,883
-0.8% -$80.8K ﹤0.01% 1867
2022
Q2 		$7.66M Sell
348,862
-730,170
-68% -$17M ﹤0.01% 2026
2022
Q1 		$48.4M Buy
1,079,032
+29,372
+3% +$1.21M 0.01% 1021
2021
Q4 		$45M Buy
1,049,660
+18,002
+2% +$941K 0.01% 1089
2021
Q3 		$68.6M Sell
1,031,658
-106,594
-9% -$7.5M 0.02% 930
2021
Q2 		$83.5M Buy
1,138,252
+111,547
+11% +$7.37M 0.02% 898
2021
Q1 		$70.3M Sell
1,026,705
-92,418
-8% -$6.95M 0.02% 928
2020
Q4 		$75.1M Buy
1,119,123
+1,035,819
+1,243% +$56.1M 0.02% 868
2020
Q3 		$4.29M Buy
83,304
+66,367
+392% +$2.95M ﹤0.01% 2079
2020
Q2 		$638K Buy
+16,937
New +$579K ﹤0.01% 3017

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's CSTL Position: Q2 2026 in Review

Invesco reduced its Castle Biosciences (CSTL) stake by 10% in Q2 2026, selling an estimated $136K and leaving 54,888 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Invesco first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $83.5M in Q2 2021. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Invesco held 54,888 shares of Castle Biosciences worth $1.31M as of Q2 2026.
  • Invesco sold 6,124 Castle Biosciences shares in Q2 2026, an estimated $136K.
  • Castle Biosciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2786 holding.
  • Invesco first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Invesco's Castle Biosciences position peaked at $83.5M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.